Although patent expirations continue to depress revenue, AstraZeneca executives believe in the pipeline.
For Bayer, the acquisition of Monsanto is intended to build its Crop Science division; meanwhile two significant approvals and two new hires enhance progress in oncology.
After years of hope and hype, Bristol-Myers Squibb’s centerpiece immuno-oncologic Opdivo is delivering the dollars.
With sales of Harvoni and Sovaldi falling off, Gilead welcomed two new blockbusters to the company’s portfolio in 2016.
Management set out a series of new priorities to 2020 to improve innovation, performance and trust in GlaxoSmithKline.
With proven worldwide commercial capabilities and a robust product pipeline, Johnson & Johnson is firmly positioned to continue generating strong, long-term, sustainable growth.
New CEO David Ricks took over Lilly as the company continues to climb out of its post-Cymbalta/Zyprexa rut.
Easily the fastest grower in Merck’s portfolio, the oncology drug Keytruda is piling up dollars and indications at an impressive rate.
2017 is serving as another challenging year for Novartis as the company continues to work through the Gleevec/Glivec patent expirations that began in 2016, but management is confident that a new phase of growth will start in 2018.
Novo Nordisk executives believe that the company is on a path that will create growth in 2017 and beyond.